CRIS Current Research Information System

TASSINARI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.212
NA - Nord America 702
EU - Europa 601
SA - Sud America 118
AF - Africa 83
Totale 3.716
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 680
SG - Singapore 648
CN - Cina 606
VN - Vietnam 443
IT - Italia 230
HK - Hong Kong 193
KR - Corea 158
NL - Olanda 104
BR - Brasile 78
IN - India 54
DE - Germania 45
FR - Francia 42
CI - Costa d'Avorio 32
JP - Giappone 31
FI - Finlandia 27
GB - Regno Unito 24
SC - Seychelles 23
ZA - Sudafrica 21
SE - Svezia 20
CH - Svizzera 18
RU - Federazione Russa 18
IE - Irlanda 17
AT - Austria 16
AR - Argentina 15
CA - Canada 14
PH - Filippine 13
JO - Giordania 12
BG - Bulgaria 11
PL - Polonia 10
BD - Bangladesh 9
TH - Thailandia 9
CL - Cile 8
ID - Indonesia 7
LT - Lituania 6
PK - Pakistan 5
TR - Turchia 5
VE - Venezuela 5
CO - Colombia 4
EC - Ecuador 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
ES - Italia 3
MX - Messico 3
SA - Arabia Saudita 3
TW - Taiwan 3
DZ - Algeria 2
IL - Israele 2
IQ - Iraq 2
JM - Giamaica 2
UY - Uruguay 2
UZ - Uzbekistan 2
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
ET - Etiopia 1
HN - Honduras 1
IR - Iran 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MA - Marocco 1
MK - Macedonia 1
ML - Mali 1
NI - Nicaragua 1
OM - Oman 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
RS - Serbia 1
TN - Tunisia 1
UA - Ucraina 1
Totale 3.716
Salva come PNG Salva come JPEG
Città #
Singapore 471
Hefei 282
Hong Kong 178
Seoul 154
Ashburn 148
Ho Chi Minh City 116
Hanoi 112
San Jose 91
Santa Clara 53
Bologna 50
Beijing 41
Los Angeles 33
Abidjan 32
Boardman 32
Council Bluffs 30
Bengaluru 26
Da Nang 24
Dallas 22
Milan 22
Tokyo 20
Guangzhou 19
Johannesburg 19
Helsinki 18
Castel Maggiore 17
Dublin 17
Redondo Beach 17
Lauterbourg 16
Haiphong 15
New York 15
Amman 12
Amsterdam 12
Bern 12
Nuremberg 12
Frankfurt am Main 11
Rome 11
Sofia 11
Vienna 11
Tongling 10
Buffalo 9
Falkenstein 9
Hyderabad 9
Biên Hòa 8
Munich 8
Turin 8
Warsaw 8
Chennai 7
Lappeenranta 7
Montreal 7
Ninh Bình 6
São Paulo 6
Zhengzhou 6
Jakarta 5
London 5
Moscow 5
Paris 5
Quận Bình Thạnh 5
Shanghai 5
Thái Nguyên 5
Trieste 5
Xi'an 5
Bari 4
Boston 4
Changsha 4
Chengdu 4
Chicago 4
Columbus 4
Florence 4
Hải Dương 4
Modena 4
Nanjing 4
Phú Thọ 4
Rimini 4
Stockholm 4
Thái Bình 4
Tianjin 4
Tân Tiến 4
Belo Horizonte 3
Bắc Ninh 3
Enschede 3
Houston 3
Huế 3
Long Xuyen 3
Manchester 3
Manila 3
Mexico City 3
New Delhi 3
Orem 3
Phủ Lý 3
Quảng Ngãi 3
Quận Ba 3
Ravenna 3
Rio de Janeiro 3
San Francisco 3
Shijiazhuang 3
Telgate 3
Venice 3
Vĩnh Long 3
Wuhan 3
Zurich 3
Điện Bàn 3
Totale 2.471
Salva come PNG Salva come JPEG
Nome #
The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy 257
Insights into the impact of chromosome 3p mutations in advanced renal cell carcinoma treated with immune-based combinations or targeted therapy: A single-center experience 193
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 176
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 169
Dual-energy spectral CT in renal cell carcinoma: dawn of a brand-new era? 165
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 160
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 160
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 159
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 155
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 149
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 147
The value of molecular features in predicting efficacy of immuno-combinations in kidney cancer: just a drop in the ocean? 144
Novel Immune Checkpoint Inhibitor Targets in Advanced or Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives 144
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes 139
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report 133
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 126
The Prognostic Role of 68GA-PSMA-PET/CT in Metastatic Hormone-Sensitive Prostate Cancer: A Preliminary Analysis 108
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma 97
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 89
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges 85
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 78
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 72
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 71
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? 71
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 69
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 67
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 67
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? 67
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis 66
Pathological and Clinical Implications of Tumor Microenvironment Evaluated With Multiplex Immunohistochemistry in Testicular Embryonal Carcinoma 53
Prostate cancer and novel pharmacological treatment options - what's new for 2022? 45
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 41
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial 37
Advancements of investigational agents for renal cell carcinoma: what clinical progress have we seen in the last 5 years? 31
Totale 3.790
Salva come PNG Salva come JPEG
Categoria #
all - tutte 9.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023137 0 0 0 0 14 3 8 5 39 11 25 32
2023/2024155 10 18 13 8 14 29 4 15 11 5 18 10
2024/20251.026 44 85 60 49 80 42 52 43 17 97 198 259
2025/20262.472 303 368 264 244 246 81 342 82 405 137 0 0
Totale 3.790